ArticleTranslational medicine @ UniSa2024
Thrombocytopenia Following Isolated Surgical Aortic Valve Replacement With Inspiris Resilia Bioprosthesis.
Article in Translational medicine @ UniSa, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Thrombocytopenia (TCP) following aortic valve replacement (AVR) is a significant concern, with varying degrees of platelet count reduction observed postoperatively. This phenomenon occurs more frequently in patients undergoing surgical biological AVR compared to those receiving mechanical AVR or transcatheter aortic valve implantation (TAVI). This study aimed to investigate the incidence of TCP following surgical AVR with the Inspiris Resilia bioprosthesis compared with Carpentier Magna Ease valve. Methods: The study retrospectively collected data from 144 patients who underwent isolated AVR between January and December 2023. Patients received either the Inspiris Resilia or the Carpentier Magna Ease valve. Platelet counts were evaluated from admission to discharge, and statistical analyses were performed to identify significant variables correlated to post-operative TCP. Results: Patients receiving the Inspiris Resilia valve had higher platelet counts from postoperative day 1-3 compared to those with the Carpentier Magna Ease valve. The incidence of moderate-to-severe TCP was significantly lower in the Inspiris Resilia group. However, no significant differences in clinical outcomes, such as bleeding events and blood transfusion rates, were observed between the two groups. Conclusions: The study showed that the Inspiris Resilia valve is associated with a lower incidence of moderate-to-severe TCP compared to the Carpentier Magna Ease valve. These findings underscore the potential benefits of utilizing the Inspiris Resilia valve to mitigate the risk of TCP post-AVR. Further research with larger cohorts is warranted to validate these results and explore the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.